Global MRSA Drugs Market 2016-2020

MRSA drugs market scenario

Methicillin-resistant Staphylococcus aureus (MRSA) is a skin infection that occurs mostly in hospitals and healthcare facilities.  It is treated with commonly-used antibiotics and is highly contagious. This infection is difficult to treat because it is sometimes resistant to commonly-used antibiotics such as methicillin. As per this market research report, the aging people are highly susceptible to MRSA infections, especially in the hospital environment as their weak immune system makes them easily prone to diseases and infections. The early detection of these diseases and growing awareness of their treatment drugs will positively aid in the growth of this market in the coming years. Technavio’s market research analyst predicts the global MRSA drugs market to grow at a steady CAGR of around 1% by 2020.

Methicillin-Resistant Staphylococcus Aureus (MRSA) growth

The surge in the number of infections and infectious diseases is creating unmet needs in the market. This has propelled government-based and non-governmental institutes to take up initiatives to develop antibiotics by providing the necessary funding to the research institutes and companies. Several nations across the globe are actively providing funds to develop antibacterial drugs and fight antibacterial drug resistance and its surveillance. Such funding encourages research institutes and companies to invest more in antibiotic research, thereby resulting in the growth of this market.

MRSA drugs market forecast by drug class

• Tetracycline
• Folate antagonist
• Cephalosporin
• Lipopeptides
• Oxazolidinone
• Lipoglycopeptide

Tetracyclines prevent bacterial protein synthesis by reversibly binding to the bacterial 30S ribosomes. They act against Gram-positive and Gram-negative bacteria; however, most of the drugs develop resistance, thereby indicate limited activity. A few commonly prescribed drugs that treat the infection include tetracycline, doxycycline, and minocycline.

MRSA drugs market value based on geographical segmentation 

• Americas
• APAC
• EMEA

The Americas dominated the MRSA drugs market in 2015 and accounted for more than 71% of the overall market share. Much of the region’s growth can be attributed to the availability of better healthcare infrastructure coupled with the presence of conducive reimbursement policies and co-pay assistance programs for patients. With the adoption of favorable regulatory initiatives for the approval of antibiotics, several drug developers in the region are focusing on developing new treatment options.

MRSA drugs market forecast: Competitive landscape and key vendors

At present, the market is growing at a slow pace because of the increased use of generics. The unavailability of effective treatment options and increased development of drug resistance is leading to unmet needs in the market. This has led pushed several vendors to engage actively in R&D activities. Also, the market is expected to witness the entry of several new players during the forecast period. The vendors are focusing on both manufacturers as well as market their products with high safety and efficacy profile, to gain a competitive edge in the market.

Key vendors in the MRSA drugs market

• Allergan
• Merck
• Pfizer
• Theravance Biopharma

Key questions answered in the report include

• What will the market size and the growth rate be in 2020?
• What are the key factors driving the global MRSA drugs market?
• What are the key market trends impacting the growth of the global MRSA drugs market?
• What are the challenges to market growth?
• Who are the key vendors in the global MRSA drugs market?
• What are the market opportunities and threats faced by the vendors in the global MRSA drugs market?
• Trending factors influencing the market shares of the Americas, APAC, and EMEA.
• What are the key outcomes of the five forces analysis of the global MRSA drugs market?

Technavio also offers customization on reports based on specific client requirement.

Related reports

• Global Antibacterial Drugs Market 2015-2019
• Global Hepatitis Drugs Market 2015-2019
• Global Hospital Infection Therapeutics Market 2015-2019
• Infectious Diseases Market in the US 2015-2019